Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Boehner CJ"'
Autor:
Dutta AK; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Alberge JB; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Lightbody ED; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Boehner CJ; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Dunford A; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Sklavenitis-Pistofidis R; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Mouhieddine TH; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Cowan AN; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Su NK; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Horowitz EM; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Barr H; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Hevenor L; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Beckwith JB; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Perry J; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Cao A; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Lin Z; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Kuhr FK; Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania., Mastro RGD; Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania., Nadeem O; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Greipp PT; Department of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota., Stewart C; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Auclair D; Multiple Myeloma Research Foundation, Norwalk, Connecticut., Getz G; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Cancer Center and Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Ghobrial IM; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Publikováno v:
Cancer discovery [Cancer Discov] 2023 Feb 06; Vol. 13 (2), pp. 348-363.
Autor:
El-Khoury H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Lee DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Alberge JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Redd R; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Cea-Curry CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Perry J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Barr H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Murphy C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Sakrikar D; The Binding Site, Rochester, MN, USA., Barnidge D; The Binding Site, Rochester, MN, USA., Bustoros M; Department of Medical Oncology, Weill Cornell Medicine, New York, NY, USA., Leblebjian H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA, USA., Cowan A; Alix School of Medicine, The Mayo Clinic, Rochester, MN, USA., Davis MI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Amstutz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Boehner CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Perkins MC; The Binding Site Group, Birmingham, UK., Harding S; The Binding Site Group, Birmingham, UK., Mo CC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Kapoor P; The Mayo Clinic, Rochester, MN, USA., Mikhael J; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA; International Myeloma Foundation, North Hollywood, CA, USA., Borrello IM; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Fonseca R; Department of Medical Oncology, The Mayo Clinic, Phoenix, AZ, USA., Weiss ST; Harvard Medical School, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Karlson E; Harvard Medical School, Boston, MA, USA; Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Trippa L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rebbeck TR; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA., Getz G; Harvard Medical School, Boston, MA, USA; Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Marinac CR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: irene_ghobrial@dfci.harvard.edu.
Publikováno v:
The Lancet. Haematology [Lancet Haematol] 2022 May; Vol. 9 (5), pp. e340-e349. Date of Electronic Publication: 2022 Mar 25.
Autor:
Mouhieddine TH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard Medical School, Boston, MA, 02115, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Sperling AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard Medical School, Boston, MA, 02115, USA., Redd R; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Park J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Leventhal M; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Gibson CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Manier S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Department of Hematology, CHU, Univ. Lille, 59000, Lille, France.; INSERM UMR-S1172, 59000, Lille, France., Nassar AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA., Capelletti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Huynh D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Bustoros M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard Medical School, Boston, MA, 02115, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard Medical School, Boston, MA, 02115, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Tahri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard Medical School, Boston, MA, 02115, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Hornburg K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Dumke H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Itani MM; Massachusetts General Hospital, Boston, MA, 02114, USA., Boehner CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Liu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., AlDubayan SH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Reardon B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Keats JJ; Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA., Stewart C; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Mehr S; Multiple Myeloma Research Foundation, Norwalk, CT, 06851, USA., Auclair D; Multiple Myeloma Research Foundation, Norwalk, CT, 06851, USA., Schlossman RL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Steensma DP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Laubach JP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Ritz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard Medical School, Boston, MA, 02115, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Soiffer RJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Trippa L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.; Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA., Getz G; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.; Massachusetts General Hospital, Boston, MA, 02114, USA., Neuberg DS; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA. irene_ghobrial@dfci.harvard.edu.; Harvard Medical School, Boston, MA, 02115, USA. irene_ghobrial@dfci.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA. irene_ghobrial@dfci.harvard.edu.
Publikováno v:
Nature communications [Nat Commun] 2020 Jun 12; Vol. 11 (1), pp. 2996. Date of Electronic Publication: 2020 Jun 12.